InflaRx NV (InflaRx NV) Debt-to-Asset

: 0.01 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

InflaRx NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.41 Mil. InflaRx NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.81 Mil. InflaRx NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $131.09 Mil. InflaRx NV's debt to asset for the quarter that ended in Dec. 2023 was 0.01.

InflaRx NV Debt-to-Asset Historical Data

The historical data trend for InflaRx NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.02	0.01	0.01	0.01

Competitive Comparison

For the Biotechnology subindustry, InflaRx NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV Debt-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, InflaRx NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Debt-to-Asset falls into.

InflaRx NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

InflaRx NV's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.408	+	0.814)	/	131.089
	=	0.01

InflaRx NV's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.408	+	0.814)	/	131.089
	=	0.01

InflaRx NV (NAS:IFRX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

InflaRx NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.